Research programme: nuclear receptor subfamily 1 group F member 3 inverse agonists - Aurigene

Drug Profile

Research programme: nuclear receptor subfamily 1 group F member 3 inverse agonists - Aurigene

Alternative Names: ROR gamma inverse agonists - Aurigene

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator Aurigene Discovery Technologies
  • Class Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation

Most Recent Events

  • 15 Apr 2016 Research programme: nuclear receptor subfamily 1 group F member 3 inverse agonists - Aurigene is available for licensing as of 15 Apr 2016. www.aurigene.com
  • 05 Aug 2015 Aurigene Discovery Technologies plans to initiate IND enabling studies of an undisclosed candidate in Autoimmune disorders in India
  • 24 Jun 2014 Preclinical trials in Autoimmune disorders in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top